Longikaurin e induces apoptosis of pancreatic cancer cells via modulation of the p38 and PI3K/AKT pathways by ROS

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 388, Issue 6, 2015, Pages 623-634

  Cheng, Hai Bo ^a   Bo, Yun ^b   Shen, Wei Xing ^a   Ren, Xian Guo ^c   Tan, Jia Ni ^a   Jia, Zhi Rong ^a   Xu, Chang Liang ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Apoptosis; Longikaurin E; Pancreatic cancer cells; ROS

Indexed keywords

ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; CASPASE 3; LACTATE DEHYDROGENASE; LONGIKAURIN E; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SURVIVIN; UNCLASSIFIED DRUG; BCL2L1 PROTEIN, HUMAN; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; KAURANE DERIVATIVE; MYC PROTEIN; MYC PROTEIN, HUMAN; PROTEIN BCL X;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MTT ASSAY; PANCREATIC CANCER CELL LINE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; DRUG EFFECTS; METABOLISM; PANCREATIC NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CASPASE 3; CELL LINE, TUMOR; DITERPENES, KAURANE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; REACTIVE OXYGEN SPECIES;

EID: 84929949596     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-015-1107-4     Document Type: Article

References (58)

1. Abbruzzese JL (2002) New applications of gemcitabine and future directions in the management of pancreatic cancer. Cancer 95:941-945
2. Aranda E, Manzano JL, Rivera F, Galan M, Valladares-Ayerbes M, Pericay C, Safont MJ, Mendez MJ, Irigoyen A, Arrivi A, Sastre J, Diaz-Rubio E (2012) Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study). Ann Oncol Off J Europ Soc Med Oncol ESMO 23:1919-1925
3. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA (2004) The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 23:8571-8580
4. Ashour AA, Abdel-Aziz AA, Mansour AM, Alpay SN, Huo L, Ozpolat B (2014) Targeting elongation factor-2 kinase (eEF-2 K) induces apoptosis in human pancreatic cancer cells. Apoptos: Int J Program Cell Death 19:241-258
5. Bai J, Sui J, Demirjian A, Vollmer CM Jr, Marasco W, Callery MP (2005) Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res 65:2344-2352
6. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol: Off J Am Soc Clin Oncol 15:2403-2413
7. Cardin DB, Berlin JD (2013) Pancreas cancer on the rise: are we up to the challenge? J Natl Cancer Inst 105:1675-1676
8. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF (2008) The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 8:187-198
9. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F (2006) The c-Myc target gene network. Semin Cancer Biol 16:253-264
10. Del Poeta G, Venditti A, Del Principe MI, Maurillo L, Buccisano F, Tamburini A, Cox MC, Franchi A, Bruno A, Mazzone C, Panetta P, Suppo G, Masi M, Amadori S (2003) Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 101:2125-2131
11. Deshmukh R, Trivedi V (2013) Methemoglobin exposure produces toxicological effects in macrophages due to multiple ROS spike induced apoptosis. Toxicol In Vitro: Int J Publ Assoc BIBRA 27:16-23
12. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protoc 1:2315-2319
13. Friess H, Lu Z, Graber HU, Zimmermann A, Adler G, Korc M, Schmid RM, Buchler MW (1998) Bax, but not Bcl-2, influences the prognosis of human pancreatic cancer. Gut 43:414-421
14. Giannoni E, Buricchi F, Grimaldi G, Parri M, Cialdai F, Taddei ML, Raugei G, Ramponi G, Chiarugi P (2008) Redox regulation of anoikis: reactive oxygen species as essential mediators of cell survival. Cell Death Differ 15:867-878
15. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M, Danesi R (2006) Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther 5:1387-1395
16. Gomez-Lazaro M, Galindo MF, Melero-Fernandez de Mera RM, Fernandez-Gomez FJ, Concannon CG, Segura MF, Comella JX, Prehn JH, Jordan J (2007) Reactive oxygen species and p38 mitogen-activated protein kinase activate Bax to induce mitochondrial cytochrome c release and apoptosis in response to malonate. Mol Pharmacol 71:736-743
17. Grippo PJ, Sandgren EP (2012) Acinar-to-ductal metaplasia accompanies c-myc-induced exocrine pancreatic cancer progression in transgenic rodents. Int J Cancer J Int du cancer 131:1243-1248
18. Gross A, McDonnell JM, Korsmeyer SJ (1999) BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13:1899-1911
19. Gupta SC, Kim JH, Prasad S, Aggarwal BB (2010) Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 29:405-434
20. Hayes GM, Carrigan PE, Beck AM, Miller LJ (2006) Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. Cancer Res 66:3819-3827
21. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA: Cancer J Clinic 55:10-30
22. Johnson MI, Robinson MC, Marsh C, Robson CN, Neal DE, Hamdy FC (1998) Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. Prostate 37:223-229
23. Kuete V, Wabo HK, Eyong KO, Feussi MT, Wiench B, Krusche B, Tane P, Folefoc GN, Efferth T (2011) Anticancer activities of six selected natural compounds of some Cameroonian medicinal plants. PLoS One 6:e21762
24. Kyprianou N, King ED, Bradbury D, Rhee JG (1997) bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer J Int du cancer 70:341-348
25. Lee CJ, Dosch J, Simeone DM (2008a) Pancreatic cancer stem cells. J Clin Oncol: Off J Am Soc Clin Oncol 26:2806-2812
26. Lee CJ, Li C, Simeone DM (2008b) Human pancreatic cancer stem cells: implications for how we treat pancreatic cancer. Transl Oncol 1:14-18
27. Li D, Xie K, Wolff R, Abbruzzese JL (2004) Pancreatic cancer. Lancet 363:1049-1057
28. Liao YJ, Bai HY, Li ZH, Zou J, Chen JW, Zheng F, Zhang JX, Mai SJ, Zeng MS, Sun HD, Pu JX, Xie D (2014) Longikaurin A, a natural ent-kaurane, induces G2/M phase arrest via downregulation of Skp2 and apoptosis induction through ROS/JNK/c-Jun pathway in hepatocellular carcinoma cells. Cell Death Dis 5:e1137
29. Lin CJ, Malina A, Pelletier J (2009) c-Myc and eIF4F constitute a feedforward loop that regulates cell growth: implications for anticancer therapy. Cancer Res 69:7491-7494
30. Lin WC, Rajbhandari N, Liu C, Sakamoto K, Zhang Q, Triplett AA, Batra SK, Opavsky R, Felsher DW, DiMaio DJ, Hollingsworth MA, Morris JP, Hebrok M, Witkiewicz AK, Brody JR, Rui H, Wagner KU (2013) Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. Cancer Res 73:1821-1830
31. Liu X, Huang J, Chen T, Wang Y, Xin S, Li J, Pei G, Kang J (2008) Yamanaka factors critically regulate the developmental signaling network in mouse embryonic stem cells. Cell Res 18:1177-1189
32. Liu N, Huang H, Liu S, Li X, Yang C, Dou QP, Liu J (2014) Calcium channel blocker verapamil accelerates gambogic acid-induced cytotoxicity via enhancing proteasome inhibition and ROS generation. Toxicol In Vitro: Int J Publ Assoc BIBRA 28:419-425
33. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C, de Gramont A, Gercor G (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol: Off J Am Soc Clin Oncol 23:3509-3516
34. Martinou JC, Youle RJ (2011) Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell 21:92-101
35. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W, National Cancer Institute of Canada Clinical Trials G (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol: Off J Am Soc Clin Oncol 25:1960-1966
36. Morgensztern D, McLeod HL (2005) PI3K/Akt/mTOR pathway as a target for cancer therapy. Anti-Cancer Drugs 16:797-803
37. Nagy A, Kozma L, Kiss I, Ember I, Takacs I, Hajdu J, Farid NR (2001) Copy number of cancer genes predict tumor grade and survival of pancreatic cancer patients. Anticancer Res 21:1321-1325
38. Newman DJ, Cragg GM, Snader KM (2003) Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 66:1022-1037
39. Penninger JM, Kroemer G (2003) Mitochondria, AIF and caspases - rivaling for cell death execution. Nat Cell Biol 5:97-99
40. Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol: Off J Am Soc Clin Oncol 22:3776-3783
41. Sauer H, Wartenberg M, Hescheler J (2001) Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem: Int J Experiment Cell Physiol Biochem Pharmacol 11:173-186
42. Simeone DM (2008) Pancreatic cancer stem cells: implications for the treatment of pancreatic cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 14:5646-5648
43. Singh N, Sarkar J, Sashidhara KV, Ali S, Sinha S (2014) Anti-tumour activity of a novel coumarin-chalcone hybrid is mediated through intrinsic apoptotic pathway by inducing PUMA and altering Bax/Bcl-2 ratio. Apoptos: Int J Program Cell Death 19:1017-1028
44. Sun HD, Huang SX, Han QB (2006) Diterpenoids from Isodon species and their biological activities. Nat Prod Rep 23:673-698
45. Tang SN, Fu J, Nall D, Rodova M, Shankar S, Srivastava RK (2012) Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. Int J Cancer J Int du Cancer 131:30-40
46. Tempero MA, Berlin J, Ducreux M, Haller D, Harper P, Khayat D, Schmoll HJ, Sobrero A, Van Cutsem E (2011) Pancreatic cancer treatment and research: an international expert panel discussion. Ann Oncol: Off J Europ Soc Med Oncol / ESMO 22:1500-1506
47. Thornberry NA, Lazebnik Y (1998) Caspases: enemies within. Science 281:1312-1316
48. Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P (2008) Redox regulation of cell survival. Antioxid Redox Signal 10:1343-1374
49. van Meerloo J, Kaspers GJ, Cloos J (2011) Cell sensitivity assays: the MTT assay. Methods Mol Biol 731:237-245
50. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol: Off J Am Soc Clin Oncol 29:4548-4554
51. Wang WG, Du X, Li XN, Wu HY, Liu X, Shang SZ, Zhan R, Liang CQ, Kong LM, Li Y, Pu JX, Sun HD (2012a) New bicyclo [3.1.0] hexane unit ent-kaurane diterpene and its seco-derivative from Isodon eriocalyx var. laxiflora. Org Lett 14:302-305
52. Wang WG, Li XN, Du X, Wu HY, Liu X, Su J, Li Y, Pu JX, Sun HD (2012b) Laxiflorolides A and B, epimeric bishomoditerpene lactones from Isodon eriocalyx. J Nat Prod 75:1102-1107
53. Willis S, Day CL, Hinds MG, Huang DC (2003) The Bcl-2-regulated apoptotic pathway. J Cell Sci 116:4053-4056
54. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH (2013) Recent progress in pancreatic cancer. CA: Cancer J Clin 63:318-348
55. Xiao H, Wang J, Yuan L, Xiao C, Wang Y, Liu X (2013) Chicoric acid induces apoptosis in 3 T3-L1 preadipocytes through ROS-mediated PI3K/Akt and MAPK signaling pathways. J Agric Food Chem 61:1509-1520
56. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B (2000) Role of BAX in the apoptotic response to anticancer agents. Science 290:989-992
57. Zhang Z, Zhang C, Ding Y, Zhao Q, Yang L, Ling J, Liu L, Ji H, Zhang Y (2014) The activation of p38 and JNK by ROS, contribute to OLO-2-mediated intrinsic apoptosis in human hepatocellular carcinoma cells. Food Chem Toxicol: Int J Publ British Indust Biol Res Assoc 63:38-47
58. Zhao D, Lin F, Wu X, Zhao Q, Zhao B, Lin P, Zhang Y, Yu X (2012) Pseudolaric acid B induces apoptosis via proteasome-mediated Bcl-2 degradation in hormone-refractory prostate cancer DU145 cells. Toxicol In Vitro: Int J Publ Assoc BIBRA 26:595-602